Caribou Biosciences CRBU Stock
Caribou Biosciences Price Chart
Caribou Biosciences CRBU Financial and Trading Overview
| Caribou Biosciences stock price | 2 USD |
| Previous Close | 2.36 USD |
| Open | 2.35 USD |
| Bid | 1.78 USD x 200 |
| Ask | 3 USD x 200 |
| Day's Range | 2.31 - 2.49 USD |
| 52 Week Range | 0.96 - 3.54 USD |
| Volume | 1.96M USD |
| Avg. Volume | 1.42M USD |
| Market Cap | 241.01M USD |
| Beta (5Y Monthly) | 2.275 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.42 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12 USD |
CRBU Valuation Measures
| Enterprise Value | 143.39M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.7357143 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 21.51288 |
| Price/Book (mrq) | 2.309886 |
| Enterprise Value/Revenue | 12.799 |
| Enterprise Value/EBITDA | -1.256 |
Trading Information
Caribou Biosciences Stock Price History
| Beta (5Y Monthly) | 2.275 |
| 52-Week Change | 142.05% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 3.54 USD |
| 52 Week Low | 0.96 USD |
| 50-Day Moving Average | 2.03 USD |
| 200-Day Moving Average | 1.94 USD |
CRBU Share Statistics
| Avg. Volume (3 month) | 1.42M USD |
| Avg. Daily Volume (10-Days) | 1.88M USD |
| Shares Outstanding | 99.18M |
| Float | 94.77M |
| Short Ratio | 4.35 |
| % Held by Insiders | 8.91% |
| % Held by Institutions | 37.90% |
| Shares Short | 7.14M |
| Short % of Float | 7.48% |
| Short % of Shares Outstanding | 7.19% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1096.36% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -34.68% |
| Return on Equity (ttm) | -83.46% |
Income Statement
| Revenue (ttm) | 11.2M USD |
| Revenue Per Share (ttm) | 0.12 USD |
| Quarterly Revenue Growth (yoy) | 1.89% |
| Gross Profit (ttm) | -81400000 USD |
| EBITDA | -114156000 USD |
| Net Income Avi to Common (ttm) | -133219000 USD |
| Diluted EPS (ttm) | -1.42 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 117.63M USD |
| Total Cash Per Share (mrq) | 1.19 USD |
| Total Debt (mrq) | 26.95M USD |
| Total Debt/Equity (mrq) | 26.41 USD |
| Current Ratio (mrq) | 6.221 |
| Book Value Per Share (mrq) | 1.052 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -101251000 USD |
| Levered Free Cash Flow (ttm) | -63509124 USD |
Profile of Caribou Biosciences
| Country | United States |
| State | CA |
| City | Berkeley |
| Address | 2929 7th Street |
| ZIP | 94710 |
| Phone | 510 982 6030 |
| Website | https://cariboubio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 97 |
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Q&A For Caribou Biosciences Stock
What is a current CRBU stock price?
Caribou Biosciences CRBU stock price today per share is 2 USD.
How to purchase Caribou Biosciences stock?
You can buy CRBU shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Caribou Biosciences?
The stock symbol or ticker of Caribou Biosciences is CRBU.
Which industry does the Caribou Biosciences company belong to?
The Caribou Biosciences industry is Biotechnology.
How many shares does Caribou Biosciences have in circulation?
The max supply of Caribou Biosciences shares is 99.18M.
What is Caribou Biosciences Price to Earnings Ratio (PE Ratio)?
Caribou Biosciences PE Ratio is now.
What was Caribou Biosciences earnings per share over the trailing 12 months (TTM)?
Caribou Biosciences EPS is -1.42 USD over the trailing 12 months.
Which sector does the Caribou Biosciences company belong to?
The Caribou Biosciences sector is Healthcare.
Caribou Biosciences CRBU included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}